Vol 11, Supp. A (2020)
Case report
Published online: 2021-01-07

open access

Page views 482
Article views/downloads 256
Get Citation

Connect on Social Media

Connect on Social Media

Successful nilotinib cessation after imatinib therapy intolerance

Joanna Wącław1, Tomasz Sacha

Abstract

Taking into consideration the high efficacy of tyrosine kinase inhibitors (TKI) in the therapy of chronic myelogenous leukemia (CML) in the chronic phase, high quality of patients life is becoming a more and more important therapeutic goal reachable by limiting treatment toxicity and, optimally, obtaining treatment-free remission (TFR). This can be achieved by effective management TKIs side effects and ultimately by stopping TKI in patients who achieved a deep molecular response (DMR). Here, we present a patient with CML, who was switched to nilotinib due to imatinib intolerance. Despite very good subjective nilotinib tolerance, hyperlipidemia and hyperglycemia occurred. After a few years of sustained DMR nilotinib was discontinued. Almost one year since this decision, the patient has remained in the TFR.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Hochhaus A, Larson RA, Guilhot F, et al. IRIS Investigators. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017; 376(10): 917–927.
  2. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4): 966–984.
  3. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0 Published: November 27, 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (September 20, 2020).
  4. Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016; 30(8): 1648–1671.
  5. Rea D, Gautier JF, Breccia M, et al. Incidence of hyperglycemia by 3 years in patients (Pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib (NIL) or imatinib (IM) in ENESTnd. Blood. 2012; 120: 1686.
  6. Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017; 35(3): 298–305.
  7. Rea D, Nicolini FE, Tulliez M, et al. France Intergroupe des Leucémies Myéloïdes Chroniques. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017; 129(7): 846–854.